Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798679 · ClinicalTrials.gov registry record
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
A clinical trial of Cardiotoxicity, sponsored by University of Minnesota.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT02798679 is a study of Cardiotoxicity that has completed, run by University of Minnesota. The registered enrollment target is 40 participants, below the 645-participant average among 13 other Cardiotoxicity trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02798679, a study of Cardiotoxicity, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.
Conditions Studied
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-08 |
| Est. Completion | 2022-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02798679
The ClinicalTrials.gov registry entry for NCT02798679 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 645-participant average among 13 other Cardiotoxicity trials with a reported enrollment target (94% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiotoxicity appearing as the primary indexed condition, and to 0 interventions.
NCT02798679 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02798679 about?
NCT02798679 is a clinical study titled "Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity". The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.
What is the current status of trial NCT02798679?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2016-08. Estimated completion is 2022-09-01.
What conditions does trial NCT02798679 study?
This clinical trial studies the following conditions: Cardiotoxicity.
Who is sponsoring clinical trial NCT02798679?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02798679 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiotoxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Global Cardio Oncology Registry
RECRUITING
-
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
RECRUITING
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
A Study of Blood Pressure Control During Cancer Treatment
RECRUITING · Phase 2
-
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.